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Abstract
Background: T cell receptor (TCR) reflects the status and function of T cells. We previously developed a gene
melting spectral pattern (GMSP) assay, which rapidly detects clonal expansion of the T cell receptor b variable gene
(TCRBV) in patients with HBV by using quantitative real-time reverse transcription PCR (qRT-PCR) with DNA melting
curve analysis. However, the molecular profiles of TCRBV in peripheral blood mononuclear cells (PBMCs) and CD8
+,
CD8
- cell subsets from chronic severe hepatitis B (CSHB) patients have not been well described.
Methods: Human PBMCs were separated and sorted into CD8
+ and CD8
- cell subsets using density gradient
centrifugation and magnetic activated cell sorting (MACS). The molecular features of the TCRBV CDR3 motif were
determined using GMSP analysis; the TCRBV families were cloned and sequenced when the GMSP profile showed
a single-peak, indicative of a monoclonal population.
Results: The number of skewed TCRBV in the CD8
+ cell subset was significantly higher than that of the CD8
- cell
subset as assessed by GMSP analysis. The TCRBV11 and BV7 were expressed more frequently than other members
of TCRBV family in PBMCs and CD8
+, CD8
- subsets. Also the relatively conserved amino acid motifs were detected
in the TCRBV22, BV18 and BV11 CDR3 in PBMCs among patients with CSHB.
Conclusions: The molecular features of the TCRBV CDR3 were markedly different among PBMCs and CD8
+, CD8
-
cell subsets derived from CSHB patients. Analysis of the TCRBV expression in the CD8
+ subset was more accurate in
assessing the status and function of circulating T cells. The expression of TCRBV11, BV7 and the relatively conserved
CDR3 amino acid motifs could also help to predict and treat patients with CSHB.
Background
Hepatitis B virus (HBV) infection remains a global
health problem with more than 350 million chronically
infected people worldwide; approximately 1 million peo-
ple die from HBV-related diseases every year [1]. Nota-
bly, chronic severe hepatitis B (CSHB) is associated with
a high mortality rate; however, its pathogenesis is not
well understood. Although antiviral treatment can sup-
press viral replication, it does not promote complete
clearance of HBV. Therefore, clarifying the pathogenesis
of hepatitis B is particularly important. HBV-related
p a t h o l o g yi sm a i n l ym e d i a t e db yt h ei m m u n er e s p o n s e
to infection [2,3]. HBV-specific cytotoxic T cell (CTL)
recognition and killing of infected hepatocytes is
believed to be a key factor in infection-associated liver
damage.
T cell responses can be directed towards a variety of
specific antigens due to the diversity of the T cell recep-
tor (TCR) repertoire. T cells of different specificity
express different complementarity determining region 3
(CDR3) that vary in length or sequence [4,5]. Measuring
the frequency of specific CDR3 sequences can reflect
the degree of T cell clonal expansion and provide some
understanding of T cell function.
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chronic viral infections has become a hot topic in the
field of infectious disease. Furthermore, this is the basis
of applied research to characterize TCR profiles in a
variety of diseases and of studies that have shown that T
cells with transformed genes can be used to treat
advanced leukemia, a strategy that has achieved results
in the clinic [6]. In this study, lymphocyte subsets were
sorted using magnetic bead separation technology, and
the distribution features of the T cell receptor b variable
gene (TCRBV) CDR3 in PBMCs from patients with
CSHB were investigated. Additionally, the CDR3 motif
expressed in CD8
+ and CD8
- cell subsets was also
characterized.
Materials and methods
Enrollment of patient population
Forty-two patients with CSHB admitted to the
Department of Infectious Disease, First Affiliated Hos-
pital, College of Medicine, Zhejiang University,
between September 2010 and March 2011, were
included in the present study. All subjects had been
HBsAg-positive for at least 12 months. Co-infection
with human immunodeficiency virus (HIV), hepatitis
A virus (HAV), hepatitis C virus (HCV), hepatitis D
v i r u s( H D V ) ,a n dh e p a t i t i sEv i r u s( H E V )w e r e
excluded by laboratory testing. The patients with
CSHB had a serum alanine aminotransferase (ALT)
level > 40 IU/L, a total bilirubin (TBiL) level > 170
μmol/L, and a plasma prothrombin activity (PTA) <
40% [7]. Patient characteristics at the time of the
study are shown in Table 1. Peripheral blood samples
were collected after informed consent was obtained
from each patient and healthy control. This study was
conducted according to the guidelines of the Declara-
tion of Helsinki; the Zhejiang University medical
ethics committee approved all procedures involving
human subjects.
Study design
GMSP analyses were perform e du s i n gP B M C sf r o m2 7
patients with CSHB, and PBMCs from 15 patients were
sorted into CD8
+ cells and CD8
- cells (i.e., the remain-
ing cell fraction) using immunomagnetic beads, then the
TCRBV profile was assessed. The skewed rates of each
biased TCRBV families were calculated, and the mono-
clonal TCRBV was cloned and sequenced. Additionally,
the relationship among the skewed TCRBV families of
PBMCs and CD8
+, CD8
- cell subsets was analyzed.
Biochemical and serological markers evaluation
Liver function was assessed by serum ALT, AST, and
TBiL levels. These assays were determined using an
automatic biochemical analyzer (HITACHI 7600, Japan).
The qualitative determination of HBV markers (HBsAg/
anti-HBs, HBeAg/anti-Hbe and anti-HBc) and other bio-
chemical and serological markers was performed in the
Central Clinical Laboratory of our unit.
Quantification and determining genotype of HBV DNA
The serum HBV DNA level was quantified using a real-
time fluorescence quantitative commercial kit (Shenzhen
PG Biotech, Shenzhen, China) with a lowest limit of
detection equal to 500 viral genome copies/mL, and the
HBV genotypes were determined as reported in an ear-
lier study [8].
PBMCs separated, CD8
+ cell sorted and purity assessment
Peripheral venous blood samples were obtained after
liver disease was diagnosed, prior to anti-viral treatment.
PBMCs from 42 CSHB patients were isolated from fresh
EDTAK2 anti-coagulated blood using Ficoll-Paque
(CEDARLANE, Netherlands) density gradient centrifu-
gation. For 15 samples, CD8
+ cells were positively
selected from PBMCs using anti-CD8 antibody-coated
magnetic beads according to the directions of the manu-
facturer (Dynal Biotech, Norway), and the remaining
fraction was depleted of CD8
+ cells (CD8
- cells). Purity
of the separated subsets were tested by FCM analysis
using PE- labeled anti- CD8 and FITC- labeled anti-
CD4 monoclonal antibodies, and the CD8
+ cell popula-
tion was found to be > 95% pure (results not shown).
cDNA synthesis and real-time PCR
Total RNA was extracted from PBMCs (CD8
+ or CD8
-
cell subsets) using a SV Total RNA Isolation System
(Promega, USA) according to the manufacturer’s direc-
tions. RNA purity and concentration were determined
by the optical density (OD) assessed using a spectro-
photometer (Bio-rad, USA). Total RNA was immediately
reverse transcribed to cDNA using the RevertAid™
First Strand cDNA Synthesis Kit (MBI, EU). Briefly, 1~5
μg total RNA was reverse transcribed with OligodT18 as
Table 1 Clinical features of the CSHB patients at entry to
the study
Characteristics All patients (n = 42)
Sex (male/female) 29/13
Mean age (in years)† 45.6 ± 8.3
Duration of infection (years)† 14.2 ± 9.1
ALT level (IU/L)† 68.8 ± 75.3
Total bilirubin level (μmol/L)† 363.2 ± 173.5
HBV DNA (lg, copies/mL)† 4.5 ± 1.6
HBeAg-positive patients‡ 16 (38.1%)
HBV genotypes 15B, 27C
CSHB, chronic severe hepatitis B; ALT: alanine amino transferase; Normal
values: ALT, ≤ 40 IU/L; total bilirubin, ≤ 21 μmol/L. †Data are expressed as
mean ± SD; ‡ Data are expressed as no. (%).
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1:2 before being used as a template for real-time PCR
with SYBR green dye. The GoTaq
® qPCR Master Mix
(Promega, USA) was selected as the PCR kit, and the
real-time PCR (dye method) reaction parameters were
as follows: 2 min of incubation at 95°C to activate the
GoTaq enzyme, followed by 45 cycles of denaturation at
95°C for 15 s, annealing at 56°C for 20 s, and extension
at 72°C for 25 s, and the fluorescence signal was
acquired at the end of every cycle. At the end, a final
extension was performed at 72°C for 8 min, following
the gene melting analysis. The experiment details were
described in our previous study [9].
Skewed clonal expansion of TCRBV gene families
After the gene melting step was complete, the melting
curve for the 24 TCRBV gene families was obtained. The
melting peak can be determined by plotting the negative
first derivative of the decrease in fluorescence signal ver-
sus temperature (-dF/dT) versus temperature (Tm); this
technique is called the Gene Melting Spectral Pattern
(GMSP) analysis as we previously reported [9]. The
skewed clonal expansion was defined using the profile of
each GMSP image displayed by the software (Opticon
Monitor 3.0) attached to the MJ Opticon 2 DNA engine
(Bio-rad, USA), and included two categories: 1) “Oligo-
clonal expansion”, appearing as a main peak associated
with other small peaks on the GMSP, and a small peak
with a height less than half the height of the main peak;
a n d2 )t h e“Monoclonal” category, with only one main
peak, and a very short small peak or no additional peak.
Cloning and sequencing
When the GMSP analysis of a sample demonstrated a
TCRBV family monoclonal profile (single peak), the cor-
responding TCRBV gene family was selected for cloning
and sequencing to characterize and determine the
degree of homogeneity within the CDR3 region. The
brief steps were following, the cDNA of the TCRBV
gene family was amplified again using GoTaq DNA
polymerase (Promega, USA) under the conditions: pre-
incubation at 95°C for 2 min to denature target cDNA,
95°C for 40 s, annealing at 56°C for 40 s, and extension
at 72°C for 60 s, for 40 cycles of amplification. PCR pro-
ducts were separated using 2% (0.5% Tris-buffered
EDTA) agarose gels (FMV BioProducts, Rockland, ME),
excised, and purified using a QIAEX gel extraction kit
(Qiagen, German). Purified products were ligated into
pGEMT-T easy vector using the pGEM-3Z Cloning Kit
(Promega, USA) according to the manufacturer’s
instructions. The plasmid DNA was sequenced in an
ABI3730 DNA Sequencer (Applied Biosystems, USA).
The results sequenced were analyzed against a standard
TCRBV gene database http://www.imgt.org.
Statistical analysis
Differences in data between two groups were examined
using a c
2-test or Student’s t-test, with a P <0 . 0 5c o n -
sidered significant. Statistical analysis was performed
using SPSS 16.0 software (SPSS Inc., Chicago, USA).
Results
Skewed TCRBV repertoire within total PBMCs and CD8
+,
CD8
- subsets
The CD8
+ and CD8
- PBMC, which were mostly CD4
+,
were obtained using magnetic sorting. The TCRBV
CDR3 profiles were compared between two sorted cell
populations (15 samples sorted) and the 27 PBMCs
populations isolated from patients with CSHB. Among
the three groups of cell populations evaluated, the
TCRBV families in the CD8
+ cells from patients con-
tained a greater number of skewed-clonally expanded
TCRBV families. The average number of skewed (oligo-
clonal and monoclonal) TCRBV families in the CD8
-
PBMC fraction was lower than the PBMCs and the CD8
+ subset (P < 0.01), and there was no significantly differ-
ence between the two latter groups (P > 0.05). Addition-
ally, there were a higher number of patients with a
normal TCRBV pattern in the CD8
- fraction compared
to the other two cell fractions (Table 2). There was a
greater number of skewed clone expansion of TCRBV
families expressed in the CD8
+ PBMC compared to the
CD8
- cells (Table 3, Figure 1).
GMSP profile of monoclonal TCRBV in total PBMCs and
CD8
+, CD8
- subsets
The profile of the TCRBV families expressed by total
PBMCs and CD8
+, CD8
- fractions was determined using
GMSP analysis. Although, the number of single-peaks
and biased-peaks for the 24 TCRBV families detected
from the three cell populations (total PBMCs and CD8
+,
CD8
- cell subsets) differed among the CSHB patients,
the two skewed TCRBV gene families (BV7, BV11) were
more prevalent than other TCRBV families (Table 2 and
3). A representative GMSP profile of a monoclonal
TCRBV expressed in PBMCs and in the CD8
+ and CD8
-
subsets is shown in Figures 2 and 3, respectively.
TCRBV CDR3 amino acid motifs in total PBMCs and CD8
+,
CD8
- subsets
The monoclonal expansion of TCRBV CDR3 gene
families were cloned, sequenced, and translated to corre-
sponding amino acid sequences. The representative
amino acid sequences of the TCRBV CDR3 from
PBMCs and CD8
+ and CD8
- subsets from patients with
C S H Ba r es h o w ni nT a b l e4a n d5 .W ef o u n dt h a t ,
among different CSHB patients, the monoclonal expan-
sion of TCRBV CDR3, such as BV22 (DLGVAQ with
BJ2.7), BV18 (RTGDTEA with BJ1.1) and BV11 (AGEL
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lar. However, when we compared the monoclonal
expansion of TCRBV CDR3 in the CD8
+ and CD8
- cell
subsets, the amino acid sequence of TCRBV18 CDR3,
(RTGDTEA with BJ1.1), was similar to PBMCs, as was
the sequences of TCRBV11 (AGEL with BJ2.2 or
VYNEQ with BJ2.1) and TCRBV5.2 (LTAGAYTGEL
with BJ2.2).
Discussion
HBV infects a narrow host range, and the lack of ideal
animal models or the efficient cell culture system greatly
limits the study of the HBV-specific immune response
[10]. In recent years, research results show that the
HBV antigen-induced cellular immune response neces-
sary for viral clearance, especially the activity of HBV-
specific CTL, also mediates HBV-associated liver inflam-
mation and damage [11,12].
T lymphocytes are composed of mainly CD4
+ and
CD8
+ cells. There are characteristic TCR molecular
chains expressed on the surface of T cells. In peripheral
blood from healthy donors, the TCR of more than 95%
of T cells is composed of alpha and beta chain heterodi-
mers, i.e., abT cells [13]. Each T cell clone expresses a
unique TCR that recognizes antigen-derived peptide
bound to major histocompatibility complex (MHC),
Table 2 The frequency of skewed TCRBV in CD8
+ and CD8
- cells (PBMCs excluding CD8
+ cell) and PBMCs from patients
with CSHB
a
TCRBV families CD8
+ cell Incidence (%)
b CD8
- PBMC Incidence (%)
b Total PBMCs Incidence (%)
b
12 0 3
2 4 (28.6) 1 4
33 0 4
43 3 6
5.1 4 (28.6) 3 7 (28)
5.2 5 (35.7) 1 4
63 0 4
7 4 (28.6) 5 (38.5) 9 (36)
8 2 0 7 (28)
92 0 6
10 0 1 2
11 9 (64.3) 9 (69.2) 15 (60)
12 5 (35.7) 2 6
13.1 3 1 7 (28)
13.2 5 (35.7) 0 7 (28)
14 2 0 3
15 2 1 2
16 3 0 3
17 5 (35.7) 2 5
18 5 (35.7) 1 8 (32)
19 0 0 1
20 4 (28.6) 4 (30.1) 4
21 4 (28.6) 1 3
22 6 (42.9) 3 5
23 1 2 5
24 3 1 1
Total no. of skewed Vb
(average ratio for a case)
89 (6.36)
c, d 41 (3.15)
c 131 (5.24)
c, d
No. of patients examined
with normal pattern (ratio, %)
1 (6.67)
e 2 (13.33)
e 2 (7.41)
e
No. of patients examined 15 15 27
aThe number of TCRBV gene families showing skewed-clone expansion (oligoclonal or monoclonal) is summarized in patients with CSHB.
bThe number of samples showing a skewed-clone expansion in total detected samples (percentages of each TCRBV skewed-clone expansion). Samples with
normal GMSP (no skewed-clone expansion pattern) are excluded in the percentage calculation.
cThe average expansion rate of TCRBV gene families was lower in CD8
- PBMC (depleted CD8
+ cells) than in other two cell populations (P < 0.01 by c
2 test).
dThere was no significant difference between the two groups (P > 0.05 by c
2 test). Sample with normal GMSP (no skewed-clone expansion pattern) are excluded
in the average ratio calculation.
eThe incidence of the normal GMSP was significantly higher in CD8
- PBMC (depleted CD8
+ cells) than in other two cell populations (P < 0.01 by c
2 test).
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function. The TCR has three complementary determin-
ing regions (CDR1, CDR2 and CDR3). CDR3 is the key
determinant of T cell antigen specificity and mediates T
cell diversity [4,14]. Therefore, analysis of the CDR3
profile reflects changes in the T cell population stimu-
lated by a specific antigen [15,16]. This may aid in
determining the effectiveness of the T cell response. For
analysis of the TCR repertoire, the b chain is often pre-
ferred because of the lower number of gene families
associated even though a higher overall sequence varia-
b i l i t yo fs e q u e n c ec o m p a r e dt ot h ea-chain has been
reported [17].
Several approaches have been used to determine the
expansion of TCRBV subgroups including Northern
blotting, semi-quantitative PCR using radioisotope-con-
jugated probes [18], or fluorescence activated cell sort-
ing (FACS) using fluorochrome-conjugated monoclonal
antibodies (mAbs) specific to TCRBV subgroups [19] or
direct quantification and characterization of CD8
+ T
cells using tetramer staining and intracellular cytokine
staining. At present, the spectratyping (immunoscope)
based on PCR was developed as the current standard in
TCRBV repertoire analysis [4,16]. However, these
approaches are susceptible to cross-contamination,
laborious, and time consuming because they require
PCR amplification, isolation of individual bands based
on DNA size, and purification, followed by repeated
cloning and sequencing.
Recently, quantitative real-time reverse transcription
PCR (qRT-PCR) has become a widely accepted method
for rapid and reproducible quantification of gene expres-
sion. Most previous attempts to quantify TCRBV
expression using qRT-PCR have utilized one primer
directed at the gene encoding the TCR constant region
of the beta chain (BC) and another primer or fluoro-
genic probe directed towards the gene encoding the
beta chain variable region (BV) [20-22]. In the current
study, we examined the molecular features of the CDR3
motif from isolated PBMCs and CD8
+ and CD8
- subsets
from patients with CSHB using GMSP analysis. The
Table 3 GMSP assay-generated profile of skewed TCRBV gene families in CD8
+ and CD8
- cells in patients with CSHB
Patients no. CD8
+ cells CD8
- cells
Skewed TCRBV Monoclone Skewed TCRBV Monoclone
1 3, 5.2, 7, 13.1, 18, 20 7, 13.1 7, 11 7, 11
2 5.1, 5.2, 7, 11, 12, 21, 22, 24 11 None None
3 3, 5.1, 17, 20, 23 None 2, 7, 11, 20 11, 20
4 4, 5.2, 11, 12, 18, 21, 22 11 7, 11 None
5 2, 13.2, 15, 16 2, 16 4, 13.1 None
6 3, 5.2, 17, 22 17 5.1, 11, 17, 22, 23 11
7 4, 6, 8, 11, 12 11 4, 7, 11 4, 7, 11
8 None None None None
9 6, 8, 11, 13.1, 13.2, 14, 16, 22 11, 13.1 5.1, 11, 17, 22, 23 11
10 9, 11, 13.1, 13.2, 16, 17, 21, 22, 24 11, 13.2 5.1, 12, 20 None
11 2, 5.2, 9, 11, 12, 14, 15,18 5.2, 11, 18 11, 20, 24 11, 24
12 3, 7, 11, 13.1, 20, 21 7, 11, 20 4 4
13 2, 5.1, 6, 13.2, 17, 18, 22, 24 6, 17 10, 11, 15, 22 11
14 1, 4, 7, 11, 17, 18 11, 18 5.2, 7, 11, 18, 20 11, 18
15 2, 5.2, 12, 13.2, 20 None 12, 21 None
Total no. of altered (skewed) TCRBV families (no. of patients) 89 (15)
a 22 (15)
b 41 (15)
a 15 (15)
b
a The rate of skewed TCRBV families was higher in CD8
+ cells than in CD8
- cells (P < 0.01 by c
2 test).
b The monoclonal rate was not significantly different
between the two groups (P> 0.05 by c
2 test).
Figure 1 Comparing the number of skewed TCRBV CDR3
between CD8
+ and CD8
- cell subsets in representative CHSB
patients (corresponding to P9-13, Table 3). Data for additional
comparisons are provided in table 3. CD8
+ cell, purified CD8
+ T
lymphocytes; CD8
- cell, PBMCs depleted of CD8
+ cells; CSHB,
chronic severe hepatitis B.
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Page 5 of 9Figure 2 Representative GMSP with a single-peak (monoclonal expansion) of TCRBV in the PBMCs from patients with CSHB. The TCRBV
gene families shown above in the top graphs correspond to P69 (BV23), P90 (BV22), P75 (BV22), P90 (BV18), P75 (BV18), and P105 (BV18); the
TCRBVs shown on the bottom graphs correspond to P107 (BV11), P131 (BV11), P83 (BV11), P71 (BV11), P69 (BV9) and P172 (BV7). The
corresponding amino acid sequences are shown in Table 4. The melting temperature is on the x-axis of each plot. The negative first derivation
of the decrease in fluorescence versus temperature (-dF/dT) is shown on the y-axis.
Figure 3 Representative GMSP with single-peak (monoclonal expansion) TCRBV in the CD8
+ cell and CD8
- cell from patients with
CSHB. The TCRBV gene families shown on the top graphs correspond to P89CD8
+ (BV18), P133CD8
+ (BV11), P115CD8
+ (BV11), and P84CD8
+
(BV1); the TCRBVs shown in the bottom graphs correspond to P119CD8
- (BV11), P89CD8
- (BV11), P84CD8
- (BV11), and P89CD8
+ (BV5.2). The
corresponding amino acid sequences are shown in Table 5. The melting temperature is on the x-axis of each plot. The negative first derivation
of the decrease in fluorescence versus temperature (-dF/dT) is shown on the y-axis.
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melting curve technique and developed for detecting the
TCRBV gene family as reported in our previous publica-
tion [9].
In peripheral blood, the number of CD4
+ Tc e l l si s
approximated 1.5 times greater than the number of the
CD8
+ T cell; this may impact analysis of TCR repertoire.
In this study, we directly analyzed the degree of skewed
clonally expanded TCRBV families in purified PBMCs
from 27 CSHB patients. We found that the average
number of skewed TCRBV families was 5.24, but within
the CD8
+ and CD8
- subsets, the average number was
6.36 and 3.15, respectively. In summary, the number of
skewed TCRBV in the CD8
- fraction was significantly
lower than in the CD8
+ cells. This is consistent with
previous reports demonstrating that proliferating HBV-
antigen specific T cells were CD8
+ T cells rather than
CD4
+ [23]. The skewed TCRBV families among the
three cell groups were different, implying that it may be
more accurate to analyze the molecular features of the
CDR3 motif in sorted T cells. Although the positive
selection of CD8
+ cells results in a CD8
- fraction that
contains a residual number of CD8
+ cells and includes
B cells, natural killer cells and some mononuclear cells,
this “contamination” has relatively little impact on the
GMSP profile of the TCRBV CDR3s within the total
CD8
- cell subset [19].
In recent years, TCR gene transfer has been developed
as a reliable method to generate large numbers of T
cells ex vivo with given antigen-specificity and
Table 4 Representative amino acid sequences of monoclonal TCRBV families in PBMCs from CSHB patients
Patients Vbeta CDR3 BJ Ratio
69 BV23 SALYFCASS VEGGNTI YFGEGSWLTVVED 1.3 21/21
90 BV22 SAMYFCASS DLGVAQ YFGPGTRLTVTED 2.7 9/20
75 BV22 SAMYFCASS DLGVAQ YFGPGTRLTVTED 2.7 4/18
90 BV18 SAAYFCASS RTGDTEA FFGQGTRLTVVED 1.1 21/21
75 BV18 SAAYFCASS RTGDTEA FFGQGTRLTVVED 1.1 21/21
105 BV18 SAAYFCASS RTGDTEA FFGQGTRLTVVED 1.1 21/21
107 BV11 SQYLCASS AGEL FFGEGSRLTVLED 2.2 5/21
131 BV11 SQYLCASS AGEL FFGEGSRLTVLED 2.2 9/20
138 BV11 SQYLCASS AGEL FFGEGSRLTVLE 2.2 9/18
172 BV11 SQYLCASS AGEL FFGEGSRLTVLED 2.2 3/21
172 BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 4/21
75 BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 7/8
83 BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 20/20
71 BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 21/21
69 BV9 SAVYFCASS LQAGRGEQ FFGPGTRLTVLED 2.1 12/20
172 BV7 SALYLCASS QDSVTTGAQ YFGPGTRLLVLED 2.5 15/21
90 BV6 SAVYLCASS LAWEEQETQ YFGPGTRLLVLED 2.5 21/21
81 BV5.2 SALYLCASS LTAGAYTGEL FFGEGSRLTVLED 2.2 10/22
2 BV5.1 SALYLCASS LEWGASYEQ YFGPGTRLTVTED 2.7 9/20
When the GMSP displayed a single peak (Figure 2), the cDNA of corresponding TCRBV family was re-amplified and PCR product was sequenced after cloning. The
amino acid sequences of the max rate of TCRBV families are shown.
Table 5 Representative amino acid sequences of monoclonal TCRBV families in CD8
+ and CD8
- cells (depleted CD8
+
cells) from CHSB patients.
Patients
a Vbeta CDR3 BJ Ratio
89 (CD8
+) BV18 SAAYFCVSS RTGDTEA FFGQGTRLTVVED 1.1 11/11
133 (CD8
+) BV11 SQYLCASS AGEL FFGEGSRLTVLED 2.2 11/20
115 (CD8
+) BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 14/16
84 (CD8
+) BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 27/27
119 (CD8
-) BV11 SQYLCASS AGEL FFGEGSRLTVLED 2.2 14/22
89 (CD8
-) BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 18/20
84 (CD8
-) BV11 SQYLCATG VYNEQ FFGPGTRLTVLED 2.1 17/20
89 (CD8
+) BV5.2 SALYLCASS LTAGAYTGEL FFGEGSRLTVLED 2.2 11/29
When the GMSP displayed a single peak (Figure 3), the cDNA of corresponding TCRBV family was re-amplified and PCR product was sequenced after cloning. The
amino acid sequences of the max rate of TCRBV families are shown.
a The cell subset for analysis in brackets.
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application [24-29]. TCR re-directed HBV-specific T
cells generated from the PBMCs of chronic HBV and
HBV-related HCC patients were shown to be multifunc-
tional and capable of recognizing HBV infected cells
and HCC tumor cells expressing viral antigens from
naturally integrated HBV DNA [30]. Thus, characteriza-
tion of the HBV-specific T cells, especially their TCR
gene usage [31], is essential for the elucidation of the
pathogenesis of HBV infection and for the development
of individualized treatment.
In the current study, we found that the monoclonal
populations expressing TCRBV7 or BV11 molecule were
more prevalent compared with other TCRBV families
used, regardless of the CDR3 in PBMCs, CD8
+ or CD8
-
subsets from CSHB patients. We also found the two
CDR3 amino acid sequences had conserved motif
(BV11, AGEL or VYNEQ and BV7, QDSVTTGAQ),
and, among different CSHB patients, the amino acid
motifs in the TCRBV22, BV18 and BV11 CDR3 in
PBMCs were similar, respectively. At present, although,
it is not clear if or how the emergence of the TCRBV
families influences the course of CSHB, in a follow-up
study, we observed an interesting phenomenon, when
CSHB patients expressed the TCRBV11 CDR3 amino
acid sequence “AGEL”, their short-term response to
treatment was better than patients expressing the
T C R B V 1 1C D R 3s e q u e n c e“VYNEQ”.M o r e o v e r ,t h e
relatively conservative TCRBV gene families may help
produce antigen-specific T cells using TCR gene transfer
for the treatment of liver disease.
Conclusion
In this report, the molecular features of the CDR3 motif
in PBMCs and in CD8
+ and CD8
- subsets isolated from
patients with CSHB were explored using GMSP ana-
lyses. During inflammatory episodes in patients with
HBV infection, the skewed TCRBV in CD8
+ subset was
significantly larger than in the CD8
- subset. This may
help to explain the underlying mechanisms of HBV
pathogenesis and may be related to impaired viral clear-
ance and repeated HBV infection [32], although, this
requires further investigation. The identification of the
relatively conserved amino acid sequences of the
TCRBV7, BV11 and other member of TCRBV family
expressed in this patient population could be used in
evaluating the health status of patients with CSHB, and
may aid in the development of transduction gene ther-
apy for patients infected with HBV.
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